NHT has assembled a highly qualified and experienced team to develop the DryNeb, as well as accompanying drug/device products that utilize the DryNeb. The company’s advisory board comprises experienced pulmonary drug delivery experts who are knowledgeable in patient care, drug formulation, device engineering, efficacy, and clinical trials – all important to the platform technology and drug/device product development.  A special thanks to our investors for their support and partnership.